» Articles » PMID: 29763369

Adipose Y5R MRNA is Higher in Obese Than Non-obese Humans and is Correlated with Obesity Parameters

Overview
Specialty Biology
Date 2018 May 16
PMID 29763369
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Neuropeptide Y is mainly expressed in the central nervous system to regulate food intake via its receptors, Y receptors, and in various peripheral tissues including adipose tissue. The objectives of this study were to compare Y5R mRNA and adipocyte parameters consisting of area, width, height, and perimeter either between obese and non-obese subjects or between subcutaneous and visceral fat as well as to compare between NPY, Y1R, Y2R, and Y5R mRNA expressions in subcutaneous and visceral adipose tissues. In subcutaneous and visceral adipose tissues, Y5R was greater in obese than in non-obese humans (both P < 0.05). Y1R mRNA expression was highest followed by Y5R, Y2R, and NPY mRNA expressions, respectively, in subcutaneous and visceral adipose tissues. Visceral Y5R mRNA had positive correlations with body weight, body mass index, waist circumference, hip circumference (R ≍ 0.4), and visceral Y1R mRNA (R = 0.773), but had a negative correlation with the quantitative insulin sensitivity check index (R=-0.421) (all P < 0.05). Subcutaneous and visceral adipocyte parameters were positively correlated with body weight, waist circumference, hip circumference, and waist-to-hip ratio, with greater values of correlation coefficient shown in visceral (R ≍ 0.5-0.8) than in subcutaneous adipocytes (R ≍ 0.4-0.6, all P < 0.05). The parameters of visceral adipocytes had positive correlations with serum NPY levels (R ≍ 0.4, all P < 0.05). Y5R mRNA in visceral adipose tissue is related to increased obesity and reduced insulin sensitivity. The dominant Y receptors in subcutaneous and visceral adipose tissue might be the Y1R and Y5R. Visceral adipocytes show higher correlations with obesity parameters than subcutaneous adipocytes, suggestive of an increased risk of metabolic syndrome in visceral obesity. Y1R and Y5R in visceral adipose tissue might be targets of drug development in prevention or treatment of adiposity. Impact statement Obesity, defined as excess fat accumulation, has been increasingly diagnosed worldwide causing adverse health consequences. The novel findings of this study were that Y5R mRNA expression in both subcutaneous and visceral fat was higher in obese than non-obese subjects. Furthermore, Y5R only in visceral fat, not subcutaneous fat, was positively correlated with visceral Y1R and obesity parameters but it was negatively correlated with the QUICKI. Moreover, we found that Y1R expression was highest followed by Y5R and Y2R, respectively, in both subcutaneous and visceral fat. Our results suggested that Y5R in visceral fat was associated with increased obesity and decreased insulin sensitivity. Y1R and Y5R might be the dominant receptors that mediate the effect of NPY-induced fat accumulation in both subcutaneous and visceral adipose tissues. Y1R and Y5R in visceral adipose tissue might be targets of drug development in prevention or treatment of obesity.

Citing Articles

The Bidirectional Relationship of NPY and Mitochondria in Energy Balance Regulation.

Sousa D, Lopes E, Rosendo-Silva D, Matafome P Biomedicines. 2023; 11(2).

PMID: 36830982 PMC: 9953676. DOI: 10.3390/biomedicines11020446.


The molecular signaling of exercise and obesity in the microbiota-gut-brain axis.

Ribeiro F, Silva M, Lyssa V, Marques G, Lima H, Franco O Front Endocrinol (Lausanne). 2022; 13:927170.

PMID: 35966101 PMC: 9365995. DOI: 10.3389/fendo.2022.927170.


Cortical Transcriptomic Alterations in Association With Appetitive Neuropeptides and Body Mass Index in Posttraumatic Stress Disorder.

Stone L, Girgenti M, Wang J, Ji D, Zhao H, Krystal J Int J Neuropsychopharmacol. 2020; 24(2):118-129.

PMID: 32951025 PMC: 8611677. DOI: 10.1093/ijnp/pyaa072.


Placental Neuropeptide Y ( NPY) and NPY receptors expressions and serum NPY levels in preeclampsia.

Klinjampa R, Sitticharoon C, Souvannavong-Vilivong X, Sripong C, Keadkraichaiwat I, Churintaraphan M Exp Biol Med (Maywood). 2019; 244(5):380-388.

PMID: 30760028 PMC: 6488869. DOI: 10.1177/1535370219831437.

References
1.
Sitticharoon C, Nway N, Chatree S, Churintaraphan M, Boonpuan P, Maikaew P . Interactions between adiponectin, visfatin, and omentin in subcutaneous and visceral adipose tissues and serum, and correlations with clinical and peripheral metabolic factors. Peptides. 2014; 62:164-75. DOI: 10.1016/j.peptides.2014.10.006. View

2.
OConnell J, Lynch L, Cawood T, Kwasnik A, Nolan N, Geoghegan J . The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity. PLoS One. 2010; 5(4):e9997. PMC: 2848665. DOI: 10.1371/journal.pone.0009997. View

3.
Kos K, Baker A, Jernas M, Harte A, Clapham J, OHare J . DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue. Diabetes Obes Metab. 2009; 11(4):285-92. DOI: 10.1111/j.1463-1326.2008.00909.x. View

4.
Yulyaningsih E, Zhang L, Herzog H, Sainsbury A . NPY receptors as potential targets for anti-obesity drug development. Br J Pharmacol. 2011; 163(6):1170-202. PMC: 3144533. DOI: 10.1111/j.1476-5381.2011.01363.x. View

5.
Nway N, Sitticharoon C, Chatree S, Maikaew P . Correlations between the expression of the insulin sensitizing hormones, adiponectin, visfatin, and omentin, and the appetite regulatory hormone, neuropeptide Y and its receptors in subcutaneous and visceral adipose tissues. Obes Res Clin Pract. 2015; 10(3):256-63. DOI: 10.1016/j.orcp.2015.05.007. View